High ratios of CD8+ to CD4+ T cells indicate advanced cardiovascular aging and dysfunction in mice.  With anti-CD3 F(ab’)2 treatment, we can deplete T cell populations, but at the cost of immune resistance to pathogens. Using mathematical models and numerical simulations, can we find optimal amounts of drug, naïve, and mature CD8+ cells?